Ryvu Therapeutics S.A. Aptuit (Verona) Srl, spolka z ograniczona odpowiedzialnoscia (nalezaca do grupy Evotec) secures contract for Pharmaceutical products - ZP/CZD/062/26 Delivery of the investigational medicinal product ROMACICLIB (RVU 120) for use as part of the non-commercial MEDWAY clinical trial "Phase I study of the use of the CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive group 3 or 4 medulloblastoma"

Poland, Aug. 26 -- Poland based Ryvu Therapeutics S.A. Aptuit (Verona) Srl, spolka z ograniczona odpowiedzialnoscia (nalezaca do grupy Evotec) has secured contract from Instytut "Pomnik-Centrum Zdrowia Dziecka" for Pharmaceutical products - ZP/CZD/062/26 Delivery of the investigational medicinal product ROMACICLIB (RVU 120) for use as part of the non-commercial MEDWAY clinical trial "Phase I study of the use of the CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive group 3 or 4 medulloblastoma" . The value of the contract is worth 1732782.91 PLN .

Published by HT Digital Content Services with permission from Pivotal Sources....